fda compounding semaglutide news october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Compounded Semaglutide: Legal & Safe

Preliminary research and case observations suggest possible applications in: Gastrointestinal support, including irritation or ulcers Tendon and ligament recovery Joint discomfort or inflammation Soft tissue repair following injury or strain While promising, these uses remain investigational

Currently, there are few ongoing clinical trials with peptide polyagonists in NASH, including tirzepatide (SYNERGY-NASH

A well-rotated thigh site will outperform a repeatedly abused stomach site every time

Indications and Usage for Vyvanse VYVANSE is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older [see Clinical Studies (14.1)]

O., Bukovsky, M., Pryor, S

BMI decreased by a mean of 3.7, and EDSS (a measure of disability) and timed 25 foot walker stable